A
APRINOIA Therapeutics
Dedicated to development of imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases
About APRINOIA Therapeutics
APRINOIA Therapeutics is a clinical-stage biotechnology company focused on discovering and developing diagnostics and therapeutics for Alzheimer's Disease (AD) and other tau-associated neurodegenerative diseases, known as tauopathies. The company operates in the healthcare and biotechnology market, serving patients, research institutions, and pharmaceutical companies. APRINOIA's business model involves building comprehensive internal drug discovery and development capabilities, as well as forming integrative collaborations with world-class scientists and research institutions. The company generates revenue through licensing agreements, such as its non-exclusive licensing agreement with Celgene Corporation for the use of its novel investigational PET imaging tracer, APN-1607. APRINOIA's pipeline includes diagnostic imaging tracers, monoclonal antibodies (mAbs) specific to pathologic tau, and small molecules that bind to tau. The company aims to develop imaging biomarkers to visualize therapeutic targets and subsequently create treatments to address these targets.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- Public via SPAC 2023
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 74.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Feb 2024 | $50M | — | Undisclosed | ↗ |
| GRANT✓Other financing | Sep 2023 | $4.4M | — | Alzheimer's Drug Discovery Foundation | ↗ |
Growth signals
Latest recorded traffic for APRINOIA Therapeutics is 660 monthly website visits, down 83.5% over the last three months. APRINOIA Therapeutics's team grew 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
APRINOIA Therapeutics in the Taipei ecosystem
The APRINOIA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Alzheimer's Drug Discovery Foundation
Series A2 investors entered at this stage
- DNDaol Investment (Formerly KTB Network)
Daiwa Corporate Investment
Series B and later3 investors entered at this stage
Yantai Dongcheng Pharmaceutical
IMM Private Equity
Ross Acquisition Corp II
Other known investors3 additional known investors
National Institutes for Quantum Science and Technology
Company K Partners- SIShangPharma Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about APRINOIA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See APRINOIA Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








